Sinusitis - Pipeline Review, H2 2020

September 2020 | 120 pages | ID: S38409ACAA8EN
Global Markets Direct

Abstracts

Sinusitis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H2 2020, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 4, 4, 1, 10 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Sinusitis - Overview
Sinusitis - Therapeutics Development
Sinusitis - Therapeutics Assessment
Sinusitis - Companies Involved in Therapeutics Development
Sinusitis - Drug Profiles
Sinusitis - Dormant Projects
Sinusitis - Discontinued Products
Sinusitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Sinusitis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Sinusitis - Pipeline by AnaptysBio Inc, H2 2020
Sinusitis - Pipeline by Argenx SE, H2 2020
Sinusitis - Pipeline by Armata Pharmaceuticals Inc, H2 2020
Sinusitis - Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H2 2020
Sinusitis - Pipeline by Furen Pharmaceutical Group Co Ltd, H2 2020
Sinusitis - Pipeline by GeneOne Life Science Inc, H2 2020
Sinusitis - Pipeline by GlycoMira Therapeutics Inc, H2 2020
Sinusitis - Pipeline by Gossamer Bio Inc, H2 2020
Sinusitis - Pipeline by Precigen Inc, H2 2020
Sinusitis - Pipeline by ProclaRx LLC, H2 2020
Sinusitis - Pipeline by Quorum Innovations LLC, H2 2020
Sinusitis - Pipeline by RAPT Therapeutics Inc, H2 2020
Sinusitis - Pipeline by Sanotize Research And Development Corp, H2 2020
Sinusitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H2 2020
Sinusitis - Dormant Projects, H2 2020
Sinusitis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Sinusitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

AnaptysBio Inc
Argenx SE
Armata Pharmaceuticals Inc
Beijing Fogangren Bio-Pharm Tech Co Ltd
Furen Pharmaceutical Group Co Ltd
GeneOne Life Science Inc
GlycoMira Therapeutics Inc
Gossamer Bio Inc
IVIEW Therapeutics Inc
Kyowa Kirin Co Ltd
Lyra Therapeutics
Merck & Co Inc
Nota Laboratories LLC
OptiNose Inc
Pfizer Inc
Precigen Inc
ProclaRx LLC
Quorum Innovations LLC
RAPT Therapeutics Inc
Sanotize Research And Development Corp
Wuhan Yicheng Biotechnology Co Ltd